Glutamate for Metabolic Intervention in Coronary Surgery II

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 321 participants.

Also called NCT02592824

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 321 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02592824
Other papers using this trial's data
  • Effect of glutamate infusion on NT-proBNP after coronary artery bypass grafting in high-risk patients (GLUTAMICS II): A randomized controlled trial PLoS medicine, 2022-05 DOI, PubMed 35533197, PMC9126383 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Sweden (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02592824. Randomized; quadruple masking; primary purpose prevention. Start 2015-11-15 (actual); primary completion 2020-10-30 (actual). Results posted on 2023-12-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Glutamate for Metabolic Intervention in Coronary Surgery II
Acronym
GLUTAMICSII
Condition
Postoperative Complications
Condition
Heart Failure
Intervention (Drug)
glutamate infusion
Intervention (Drug)
saline infusion
Lead sponsor
University Hospital, Linkoeping (class: other)
Collaborator
Region Örebro County (class: other)
Collaborator
University Hospital, Umeå (class: other)
Collaborator
Sahlgrenska University Hospital (class: other)

Record details

Record id
cardio:ct-nct02592824
Content hash
ceadeba6c8aef3ccfb8abd85a24a0de47844281e04527e14040ba92ccf76ab70